The role of biomarkers for prediction of disease progression and treatment response in IgA nephropathy

This ongoing PhD-program, is a joint venture between Uppsala and Västerås, and explores gut reactivity, microbiota, gut permeability, urine proteomics, complement activation and progression in IgAN and is a continuation of a long-term focus on gut mucosal reactivity in IgAN. The planned studies follow a treatment study in patients with IgA nephropathy using a corticosteroid compound acting primarily in the gut (budesonide) that demonstrated reduction in proteinuria and stabilization of renal function (GFR).